250 related articles for article (PubMed ID: 20160479)
1. Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2A.
Bieging KT; Swanson-Mungerson M; Amick AC; Longnecker R
Cell Cycle; 2010 Mar; 9(5):901-8. PubMed ID: 20160479
[TBL] [Abstract][Full Text] [Related]
2. Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis.
Ikeda M; Hayes CK; Schaller SJ; Longnecker R
Blood Adv; 2022 Jul; 6(14):4283-4296. PubMed ID: 35605249
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.
Cen O; Longnecker R
Mol Cancer Ther; 2011 Apr; 10(4):679-86. PubMed ID: 21282357
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis.
Bieging KT; Amick AC; Longnecker R
Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17945-50. PubMed ID: 19815507
[TBL] [Abstract][Full Text] [Related]
5. Two Pathways of p27
Sora RP; Ikeda M; Longnecker R
mBio; 2019 Apr; 10(2):. PubMed ID: 30992353
[TBL] [Abstract][Full Text] [Related]
6. Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines.
Perez-Chacon G; de Los Rios C; Zapata JM
Pharmacol Res; 2014 Nov; 89():46-56. PubMed ID: 25180456
[TBL] [Abstract][Full Text] [Related]
7. How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma?
Allday MJ
Semin Cancer Biol; 2009 Dec; 19(6):366-76. PubMed ID: 19635566
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis.
Bultema R; Longnecker R; Swanson-Mungerson M
Oncogene; 2009 Mar; 28(11):1471-6. PubMed ID: 19182823
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
Niedobitek G; Agathanggelou A; Rowe M; Jones EL; Jones DB; Turyaguma P; Oryema J; Wright DH; Young LS
Blood; 1995 Jul; 86(2):659-65. PubMed ID: 7605996
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
De Leo A; Arena G; Stecca C; Raciti M; Mattia E
Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
[TBL] [Abstract][Full Text] [Related]
11. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
[TBL] [Abstract][Full Text] [Related]
12. The LCR of EBV makes Burkitt's lymphoma endemic.
Niller HH; Salamon D; Banati F; Schwarzmann F; Wolf H; Minarovits J
Trends Microbiol; 2004 Nov; 12(11):495-9. PubMed ID: 15488390
[TBL] [Abstract][Full Text] [Related]
13. The investigation of Epstein-Barr viral sequences in 41 cases of Burkitt's lymphoma from Egypt: epidemiologic correlations.
Anwar N; Kingma DW; Bloch AR; Mourad M; Raffeld M; Franklin J; Magrath I; el Bolkainy N; Jaffe ES
Cancer; 1995 Oct; 76(7):1245-52. PubMed ID: 8630905
[TBL] [Abstract][Full Text] [Related]
14. The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line.
D'Souza B; Rowe M; Walls D
J Virol; 2000 Jul; 74(14):6652-8. PubMed ID: 10864681
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma.
Fish K; Chen J; Longnecker R
Blood; 2014 Jan; 123(4):530-40. PubMed ID: 24174629
[TBL] [Abstract][Full Text] [Related]
16. EBV latent membrane protein 2A orchestrates p27
Fish K; Sora RP; Schaller SJ; Longnecker R; Ikeda M
Blood; 2017 Dec; 130(23):2516-2526. PubMed ID: 29074502
[TBL] [Abstract][Full Text] [Related]
17. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
Niller HH; Salamon D; Ilg K; Koroknai A; Banati F; Bauml G; Rucker O; Schwarzmann F; Wolf H; Minarovits J
Med Sci Monit; 2003 Jan; 9(1):HY1-9. PubMed ID: 12552250
[TBL] [Abstract][Full Text] [Related]
18. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.
Renouf B; Hollville E; Pujals A; Tétaud C; Garibal J; Wiels J
Leukemia; 2009 Sep; 23(9):1557-63. PubMed ID: 19421231
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata.
Komano J; Sugiura M; Takada K
J Virol; 1998 Nov; 72(11):9150-6. PubMed ID: 9765461
[TBL] [Abstract][Full Text] [Related]
20. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
